- $1.35bn
- $1.48bn
- $303.71m
- 56
- 18
- 68
- 45
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 250 | 252 | 251 | 276 | 304 |
Cost of Revenue | |||||
Gross Profit | 151 | 148 | 146 | 166 | 188 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 304 | 319 | 326 | 354 | 354 |
Operating Profit | -53.3 | -66.1 | -74.3 | -78.1 | -50.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -68.5 | -76.3 | -80.3 | -81.3 | -55.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -69.1 | -77 | -81.2 | -82.2 | -56.4 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -69.1 | -77 | -81.2 | -82.2 | -56.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -69.1 | -77 | -81.2 | -82.2 | -56.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.71 | -1.78 | -1.8 | -1.85 | -1.16 |